BLAINJECTIONINJECTABLEPriority Review
Approved
Feb 2014
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIMIZIM (elosulfase alfa) is a recombinant hydrolytic enzyme indicated for Morquio A syndrome (mucopolysaccharidosis IVA), a rare lysosomal storage disorder. It functions as a replacement enzyme that breaks down glycosaminoglycans that accumulate in patients with this genetic condition. The intravenous infusion addresses the underlying metabolic defect by supplementing the missing or deficient enzyme.
$0.017BPart D
PeakThe product is at peak lifecycle with modest Part D spending ($17M, 165 claims in 2023), suggesting a stable niche market with limited growth opportunities but established commercial infrastructure.
Mechanism of Action
Pharmacologic Class:
Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VIMIZIM offers stability in a rare disease specialty franchise with deep relationships in a small, well-defined patient community. Career progression may be limited by the niche indication and peak lifecycle stage, but positions candidates as rare disease experts valuable for portfolio expansion.
Brand ManagerMedical Science Liaison (MSL)
Worked on VIMIZIM at BioMarin Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.